Teva Branded Pharmaceutical Products R&D LLC
22
9
12
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
22.7%
5 terminated/withdrawn out of 22 trials
50.0%
-36.5% vs industry average
36%
8 trials in Phase 3/4
120%
6 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Role: lead
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Role: lead
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Role: lead
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Role: lead
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Role: lead
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Role: collaborator
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Role: lead
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Role: collaborator
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Role: collaborator
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Role: collaborator
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
Role: lead
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
Role: lead
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Role: lead
A Study to Assess New Formulations of TEV-56286
Role: lead
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
Role: lead
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
Role: lead
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Role: lead
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Role: lead
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
Role: lead
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
Role: lead